ArticleProceedings of the National Academy of Sciences of the United States of America2010
Salmonella-mediated delivery of RNase P-based ribozymes for inhibition of viral gene expression and replication in human cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Potential Applications of RNase P Ribozyme Against Hepatitis B Virus.Molecules (Basel, Switzerland) · 2025Review
- An OralPathogens (Basel, Switzerland) · 2025Article
- Antiviral Immune Responses Against Murine Cytomegalovirus Induced by an OralMicroorganisms · 2025Article
- Engineering of highly active gene targeting RNase P ribozyme against human cytomegalovirus infection.hLife · 2025Article
- Oral Vaccination with AttenuatedPathogens (Basel, Switzerland) · 2025Article
- Article
- Review
- In Vitro Amplification and Selection of Engineered RNase P Ribozyme for Gene Targeting Applications.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Review
- Suppressing Kaposi's Sarcoma-Associated Herpesvirus Lytic Gene Expression and Replication by RNase P Ribozyme.Molecules (Basel, Switzerland) · 2023Article
- Human RNase P: overview of a ribonuclease of interrelated molecular networks and gene-targeting systems.RNA (New York, N.Y.) · 2023Review
- Mapping of RNase P Ribozyme Regions in Proximity with a Human RNase P Subunit Protein Using Fe(II)-EDTA Cleavage and Nuclease Footprint Analyses.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Inhibition of human cytomegalovirus major capsid protein expression and replication by ribonuclease P-associated external guide sequences.RNA (New York, N.Y.) · 2019Article
- Engineered RNase P Ribozymes Effectively Inhibit the Infection of Murine Cytomegalovirus in Animals.Theranostics · 2018Article
- Inhibition of human cytomegalovirus immediate early gene expression and growth by a novel RNase P ribozyme variant.PloS one · 2017Article
- RNase P-Mediated Sequence-Specific Cleavage of RNA by Engineered External Guide Sequences.Biomolecules · 2015Review
- Ribozyme-Spherical Nucleic Acids.Journal of the American Chemical Society · 2015Article
- Article
- Strategies for viral RNA stability: live long and prosper.Trends in genetics : TIG · 2011Review
- Oral delivery of RNase P ribozymes by Salmonella inhibits viral infection in mice.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
A fundamental challenge in gene therapy is to develop approaches for delivering nucleic acid-based gene interfering agents, such as small interfering RNAs and ribozymes, to the appropriate cells in a way that is tissue/cell specific, efficient, and safe. Using human cytomegalovirus (HCMV) infection of differentiated macrophages as the model, we showed that Salmonella can efficiently deliver RNase P-based ribozyme sequence in specific human cells, leading to substantial ribozyme expression and effective inhibition of viral infection. We constructed a functional RNase P ribozyme (M1GS RNA) that targets the overlapping mRNA region of two HCMV capsid proteins, the capsid scaffolding protein (CSP) and assemblin, which are essential for viral capsid formation. Substantial expression of ribozymes was observed in human differentiated macrophages that were treated with attenuated Salmonella strains carrying the ribozyme sequence constructs. A reduction of 87-90% in viral CSP expression and a reduction of about 5,000-fold in viral growth were observed in cells that were treated with Salmonella carrying the sequence of the functional ribozyme but not with those carrying the sequence of a control ribozyme that contained mutations abolishing the catalytic activity. To our knowledge, this study showed for the first time that ribozymes expressed following targeted gene transfer with Salmonella-based vectors are highly active and specific in blocking viral infection. Moreover, these results demonstrate the feasibility to develop Salmonella-mediated gene transfer of RNase P ribozymes as an effective approach for gene-targeting applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.